An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancerAnthony Fields, M. S. Berger, L. Leopold et al.|Journal of Clinical Oncology|2005Cited by 48
Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients with Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy: Toxicity Comparison of Two Dose SchedulesJesús G. Berdeja, Ian W. Flinn, Luis Chu et al.|Blood|2012Cited by 11
Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose ChemotherapyJesús G. Berdeja, Ian W. Flinn, Michael R. Savona et al.|Blood|2013Cited by 7
Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients (Pts) with Multiple Myeloma (MM) Who Are Not Candidates for High Dose ChemotherapyJesús G. Berdeja, Ian W. Flinn, Todd M. Bauer et al.|Clinical Lymphoma Myeloma & Leukemia|2015Cited by 2